Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

927
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
927
Analgesia and Pain Management01:25

Analgesia and Pain Management

2.8K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.8K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

19.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
19.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

11.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.2K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

1.1K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.1K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unusual clinical manifestations and predominant stopgain ATM gene variants in a single centre cohort of ataxia telangiectasia from North India.

Scientific reports·2022
Same author

Kawasaki disease does not affect coronaries alone: large vessels can be involved as well.

Clinical rheumatology·2022
Same author

Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines.

Cureus·2022
Same author

Phenomic Analysis of Chronic Granulomatous Disease Reveals More Severe Integumentary Infections in X-Linked Compared With Autosomal Recessive Chronic Granulomatous Disease.

Frontiers in immunology·2022
Same author

Does Bacille Calmette-Guérin Vaccination Provides Protection against COVID-19: A Systematic Review and Meta-analysis.

Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine·2022
Same author

Management of pregnancy in hereditary angioedema in a resource constrained setting: Our experience at Chandigarh, North India.

Immunobiology·2022

Related Experiment Video

Updated: Mar 22, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

655

Endocannabinoid System: A Multi-Facet Therapeutic Target.

Rimplejeet Kaur1, Sneha R Ambwani, Surjit Singh

  • 1Department of Pharmacology, AIIMS, Jodhpur, Rajasthan, India. sidhurimple@yahoo.com.

Current Clinical Pharmacology
|April 19, 2016
PubMed
Summary

The endocannabinoid system, influenced by Cannabis sativa, shows therapeutic potential for numerous diseases. Research is ongoing to develop targeted cannabinoid-based drugs with improved efficacy and safety profiles.

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.2K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

3.0K

Related Experiment Videos

Last Updated: Mar 22, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

655
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.2K
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

3.0K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Medical Chemistry

Background:

  • Cannabis sativa, or marijuana, has a long history of recreational and medicinal use.
  • The endocannabinoid system's role in disease pathology and its protective functions are increasingly recognized.
  • Therapeutic applications of cannabinoids have been historically limited by legal restrictions and research challenges.

Purpose of the Study:

  • To explore the therapeutic potential of modulating the endocannabinoid system for various medical conditions.
  • To review current cannabinoid-based drugs and ongoing research into novel therapeutic targets.
  • To identify challenges and future directions in developing cannabinoid-acting drugs.

Main Methods:

  • Review of existing literature on the endocannabinoid system and cannabinoid-based therapeutics.
  • Analysis of approved and investigational drugs targeting cannabinoid receptors (agonists and antagonists).
  • Discussion of clinical trial outcomes, including successes and setbacks (e.g., Rimonabant, FAAH inhibitors).

Main Results:

  • Cannabinoid receptor agonists (e.g., nabilone, dronabinol, Sativex, Epidiolex) are used or investigated for chemotherapy-induced emesis, multiple sclerosis spasticity, cancer pain, and epilepsy.
  • CB1 receptor antagonists (e.g., Rimonabant) showed anti-obesity potential but were withdrawn due to psychiatric side effects.
  • Research into FAAH inhibitors faced setbacks due to adverse events, highlighting safety concerns.

Conclusions:

  • The endocannabinoid system offers promising therapeutic targets for a wide range of diseases, including pain, inflammation, neurological disorders, and metabolic conditions.
  • Developing selective cannabinoid receptor agonists and antagonists with improved safety profiles and targeted delivery (e.g., outside the blood-brain barrier) is crucial.
  • Further research is needed to fully characterize cannabinoid receptor location, function, and expression dynamics to optimize therapeutic strategies.